The investment firm noted that recently released results from the Phase 1 Helios study of Axpaxli in non-proliferative diabetic retinopathy, or NPDR, showed no notable safety issues. It added that ...

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

Diabetic retinopathy is among the top five causes ... Coordinated by Oxford Population Health, the LENS (Lowering Events in ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

He added that the totality of the data in non-proliferative diabetic retinopathy suggests clinical activity at "certain doses" and supports further clinical evaluation of the drug in this indication.

outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic ...

and findings from a clinical trial focused on non-proliferative diabetic retinopathy. Ocular is utilizing its proprietary bioresorbable hydrogel technology, ELUTYX™, in its ongoing trials ...

which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study in late ...

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P ...